07:36 AM EDT, 09/08/2025 (MT Newswires) -- Pfizer ( PFE ) and BioNTech (BNTX) said Monday that preliminary data from a phase 3 study of their LP.8.1-adapted COVID-19 vaccine, Comirnaty, showed a robust immune response.

The cohort included 50 adults aged 65 and older and 50 adults aged 18-64 with at least one underlying risk factor for severe COVID-19. All participants had previously received the KP.2-adapted vaccine at least six months earlier and had not received another COVID-19 vaccine or had the disease since the vaccination.

Results showed LP.8.1-neutralizing antibody titers increased at least four-fold 14 days after vaccination in both age groups.

The safety profile of the vaccine was consistent with previous studies, and no new concernswere detected.